Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
1988 | 1 |
2014 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Trastuzumab beyond progression for HER2 positive metastatic breast cancer: progression-free survival on first-line therapy predicts overall survival impact.
Breast J. 2014 Jul-Aug;20(4):408-13. doi: 10.1111/tbj.12284.
Breast J. 2014.
PMID: 24985529
Clinical Trial.
A total of 119 patients received a median of two lines of trastuzumab-based therapy (range 1-8). Median overall survival was 21.8 months (95% CI = 14.5-27.1 m), by era was 15.6 m (95% CI = 9.7-24.8 m) versus 26.1 m (95% CI = 20.0-39.3 m; p = 0.1 …
A total of 119 patients received a median of two lines of trastuzumab-based therapy (range 1-8). Median overall survival was 21.8 months (95 …
Results of low-dose methotrexate treatment of persistent gestational trophoblastic disease in Sheffield 1980-1987.
Dorreen MS, Pennington GW, Millar DR, Hill AS, Neal FE.
Dorreen MS, et al.
Acta Oncol. 1988;27(5):551-6. doi: 10.3109/02841868809093587.
Acta Oncol. 1988.
PMID: 2849467
Between January 1980 and October 1987, 115 evaluable patients were treated in Sheffield for persistent gestational trophoblastic disease (GTD) with a low dose methotrexate regimen (LD-MTX). Each course comprised MTX 50 mg given by i.m. injection for 4 doses on alternate da …
Between January 1980 and October 1987, 115 evaluable patients were treated in Sheffield for persistent gestational trophoblastic disease (GT …
Item in Clipboard
Cite
Cite